In last trading session, Immunome Inc (NASDAQ:IMNM) saw 0.44 million shares changing hands with its beta currently measuring 1.84. Company’s recent per share price level of $13.55 trading at $0.08 or 0.59% at ring of the bell on the day assigns it a market valuation of $845.74M. That closing price of IMNM’s stock is at a discount of -128.49% from its 52-week high price of $30.96 and is indicating a premium of 48.86% from its 52-week low price of $6.93. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.43 million shares which gives us an average trading volume of 763.45K if we extend that period to 3-months.
For Immunome Inc (IMNM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.66 in the current quarter.
Immunome Inc (NASDAQ:IMNM) trade information
Upright in the green during last session for gaining 0.59%, in the last five days IMNM remained trading in the green while hitting it’s week-highest on Friday, 11/29/24 when the stock touched $13.55 price level, adding 0.81% to its value on the day. Immunome Inc’s shares saw a change of 26.64% in year-to-date performance and have moved 43.84% in past 5-day. Immunome Inc (NASDAQ:IMNM) showed a performance of 11.07% in past 30-days. Number of shares sold short was 10.67 million shares which calculate 15.99 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 33 to the stock, which implies a rise of 58.94% to its current value. Analysts have been projecting 23 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -69.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of -69.74% for stock’s current value.
Immunome Inc (IMNM) estimates and forecasts
Statistics highlight that Immunome Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -9.30% of value to its shares in past 6 months, showing an annual growth rate of -242.75% while that of industry is 17.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -32.90% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.16M for the same. Company posted 3.83M and 1.03M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -48.48% during past 5 years.
Immunome Inc (NASDAQ:IMNM)’s Major holders
Insiders are in possession of 16.99% of company’s total shares while institution are holding 83.47 percent of that, with stock having share float percentage of 100.56%. Investors also watch the number of corporate investors in a company very closely, which is 83.47% institutions for Immunome Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at IMNM for having 3.76 million shares of worth $45.48 million. And as of 2024-06-30, it was holding 36.4624 of the company’s outstanding shares.
The second largest institutional holder is REDMILE GROUP, LLC, which was holding about 4.89 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.1579 of outstanding shares, having a total worth of $59.16 million.
On the other hand, Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 1.64 shares of worth $22.17 million or 2.62% of the total outstanding shares. The later fund manager was in possession of 1.5 shares on Jun 30, 2024 , making its stake of worth around $20.39 million in the company or a holder of 2.41% of company’s stock.
